

- Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010;127:2893–2917.
- Heck JE, Charbotel B, Moore LE, et al. Occupation and renal cell cancer in Central and Eastern Europe. *Occup Environ Med* 2010;67:47–53.
- Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. *J Pathol* 1997;183:131–133.
- Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. *Nat Rev Urol* 2010;7:277–285.
- Latif F, Tory K, Gnarr JR, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. *Science* 1993;260:1317–1320.
- Schmidt LS, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. *Nat Genet* 1997;16:68–73.
- Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. *Nat Genet* 2002;30:406–410.
- Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. *Cancer Cell* 2002;2:157–164.
- Vanharanta S, Buchta M, McWhinney SR, et al. Early-onset renal cell carcinoma as a novel extraparaganglionic component of SDHB-associated heritable paraganglioma. *Am J Hum Genet* 2004;74:153–159.
- Ricketts CJ, Shuch B, Vocke CD, et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. *J Urol* 2012;188:2063–2071.
- Malinoc A, Sullivan M, Wiech T, et al. Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3. *Endocr Relat Cancer* 2012;19:283–290.
- Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, et al. Genetic analysis of von Hippel-Lindau disease. *Hum Mutat* 2010;31:521–537.
- Zbar B, Brauch H, Talmadge C, et al. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. *Nature* 1987;327:721–724.
- Stolle C, Glenn GM, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. *Hum Mutat* 1998;12:417–423.
- Cho HJ, Ki CS, Kim JW. Improved detection of germline mutations in Korean VHL patients by multiple ligation-dependent probe amplification analysis. *J Korean Med Sci* 2009;24:77–83.
- Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. *Nat Rev Cancer* 2008;8:865–873.
- Cohen AJ, Li FP, Berg S, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. *N Engl J Med* 1979;301:592–595.
- Schmidt LS, Li F, Brown RS, et al. Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. *Cancer J Sci Am* 1995;1:191–195.
- Melendez B, Rodriguez-Perales S, Martinez-Delgado B, et al. Molecular study of a new family with hereditary renal cell carcinoma and a translocation t(3;8)(p13;q24.1). *Hum Genet* 2003;112:178–185.
- Bodmer D, van den Hurk W, van Groningen JJ, et al. Understanding familial and non-familial renal cell cancer. *Hum Mol Genet* 2002;11:2489–2498.
- Gnarr JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. *Nat Genet* 1994;7:85–90.
- Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. *Clin Cancer Res* 2008;14:4726–4734.
- Stebbins CE, Kaelin WG, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. *Science* 1999;284:455–461.
- Kondo K, Kleo J, Nakamura E, et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. *Cancer Cell* 2002;1:237–246.
- Maranchie JK, Vasselli JR, Riss J, et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. *Cancer Cell* 2002;1:247–255.
- Li M, Kim WY. Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL. *J Cell Mol Med* 2011;15:187–195.
- Roe JS, Kim H, Lee SM, et al. p53 stabilization and transactivation by a von Hippel-Lindau protein. *Mol Cell* 2006;22:395–405.
- Yang H, Minamishima YA, Yan Q, et al. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. *Mol Cell* 2007;28:15–27.
- Hergovich A, Lisztwan J, Barry R, et al. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. *Nat Cell Biol* 2003;5:64–70.
- Lutz MS, Burk RD. Primary cilium formation requires von Hippel-Lindau gene function in renal-derived cells. *Cancer Res* 2006;66:6903–6907.
- Kurban G, Duplan E, Ramlal N, et al. Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2. *Oncogene* 2008;27:1004–1012.
- Tang N, Mack F, Haase VH, et al. pVHL function is essential for endothelial extracellular matrix deposition. *Mol Cell Biol* 2006;26:2519–2530.
- Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. *Nature* 2011;469:539–542.
- Guo C, Gui Y, Gao S, et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. *Nat Genet* 2011;12:1–3.
- Dalglish GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. *Nature* 2010;463:360–365.
- Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. *Nat Genet* 2012;44:751–759.
- Farley MN, Schmidt LS, Mester JL, et al. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. *Mol Cancer Res* 2013;11:1061–1071.
- Popova T, Hebert L, Jacquemin V, et al. Germline BAP1 mutations predispose to renal cell carcinomas. *Am J Hum Genet* 2013;92:974–980.
- The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature* 2013;499:43–49.
- Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. *Curr Mol Med* 2004;4:855–868.
- Schmidt LS, Junker K, Weirich G, et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. *Cancer Res* 1998;58:1719–1722.
- Schmidt LS, Nickerson ML, Angeloni D, et al. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the Met proto-oncogene. *J Urol* 2004;172:1256–1261.
- Zbar B, Glenn GM, Lubensky IA, et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. *J Urol* 1995;153:907–912.
- Kovacs G, Fuzesi L, Emanuel A, et al. Cytogenetics of papillary renal cell tumors. *Genes Chromosomes Cancer* 1991;3:249–255.
- Schmidt LS, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. *Oncogene* 1999;18:2343–2350.
- Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. *Cancer Metastasis Rev* 2008;27:85–94.
- Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. *Nat Rev Mol Cell Biol* 2003;4:915–925.
- Jeffers M, Schmidt LS, Nakaigawa N, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. *Proc Natl Acad Sci U S A* 1997;94:11445–11450.
- Jeffers M, Fiscella M, Webb CP, et al. The mutationally activated Met receptor mediates motility and metastasis. *Proc Natl Acad Sci U S A* 1998;95:14417–14422.
- Miller M, Ginalski K, Lesyng B, et al. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. *Proteins* 2001;44:32–43.
- Zhuang Z, Park WS, Pack S, et al. Trisomy 7 - harboring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. *Nat Genet* 1998;20:66–69.
- de Jong B, Molenaar IM, Leeuw JA, et al. Cytogenetics of a renal adenocarcinoma in a 2-year-old child. *Cancer Genet Cytogenet* 1986;21:165–169.
- Sidhar SK, Clark J, Gill S, et al. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. *Hum Mol Genet* 1996;5:1333–1338.
- Weternan MJ, van Groningen JJ, Jansen A, et al. Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins. *Oncogene* 2000;19:69–74.
- Weternan MA, van Groningen JJ, den HA, et al. Transformation capacities of the papillary renal cell carcinoma-associated PRCC/TFE3 and TFE3/PRCC fusion genes. *Oncogene* 2001;20:1414–1424.
- Armah HB, Parwani AV. Xp11.2 translocation renal cell carcinoma. *Arch Pathol Lab Med* 2010;134:124–129.
- Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. *Cancer Res* 2007;67:919–929.
- Davis IJ, Hsi BL, Arroyo JD, et al. Cloning of an Alpha-TFE3 fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. *Proc Natl Acad Sci U S A* 2003;100:6051–6056.
- Bertolotto C, Lesueur F, Giuliano S, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. *Nature* 2011;480:94–98.
- Birt AR, Hogg GR, Dubé WJ. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. *Arch Dermatol* 1977;113:1674–1677.
- Toro JR, Glenn C, Duray P, et al. Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. *Arch Dermatol* 1999;135:1195–1202.
- Zbar B, Alford WG, Glenn GM, et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. *Cancer Epidemiol Biomarkers Prev* 2002;11:393–400.
- Menko FH, van Steensel MA, Giraud S, et al. Birt-Hogg-Dubé syndrome: diagnosis and management. *Lancet Oncol* 2009;10:1199–1206.
- Schmidt LS, Nickerson ML, Warren MB, et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. *Am J Hum Genet* 2005;76:1023–1033.

65. Toro JR, Wei MH, Glenn GM, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. *J Med Genet* 2008;45:321–331.
66. Toro JR, Pautler SE, Stewart L, et al. Lung cysts, spontaneous pneumothorax and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. *Am J Respir Crit Care Med* 2007;175:1044–1053.
67. Pavlovich CP, Walther MM, Eyer RA, et al. Renal tumors in the Birt-Hogg-Dubé syndrome. *Am J Surg Pathol* 2002;26:1542–1552.
68. Schmidt LS, Warren MB, Nickerson ML, et al. Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. *Am J Hum Genet* 2001;69:876–882.
69. Khoo SK, Bradley M, Wong FK, et al. Birt-Hogg-Dubé syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2. *Oncogene* 2001;20:5239–5242.
70. Leter EM, Koopmans AK, Gille JJ, et al. Birt-Hogg-Dubé syndrome: clinical and genetic studies of 20 families. *J Invest Dermatol* 2008;128:45–49.
71. Benhammou JN, Vocke CD, Santani A, et al. Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dubé syndrome. *Genes Chromosomes Cancer* 2011;50:466–477.
72. Kluger N, Giraud S, Coupier I, et al. Birt-Hogg-Dubé syndrome: clinical and genetic studies of 10 French families. *Br J Dermatol* 2010;162:527–537.
73. Kunogi M, Kurihara M, Ikegami TS, et al. Clinical and genetic spectrum of Birt-Hogg-Dubé syndrome patients in whom pneumothorax and/or multiple lung cysts are the presenting feature. *J Med Genet* 2010;47:281–287.
74. Lim DH, Rehal PK, Nahorski MS, et al. A new locus-specific database (LSDB) for mutations in the folliculin (FLCN) gene. *Hum Mutat* 2010;31:E1043–E1051.
75. Vocke CD, Yang Y, Pavlovich CP, et al. High frequency of somatic frame-shift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors. *J Natl Cancer Inst* 2005;97:931–935.
76. Gad S, Lefevre SH, Khoo SK, et al. Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. *Br J Cancer* 2007;96:336–340.
77. da Silva NF, Gentile D, Hesson LB, et al. Analysis of the Birt-Hogg-Dubé (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer. *J Med Genet* 2003;40:820–824.
78. Khoo SK, Kahnoski K, Sugimura J, et al. Inactivation of BHD in sporadic renal tumors. *Cancer Res* 2003;63:4583–4587.
79. Nagy A, Zoubakov D, Stupar Z, et al. Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma. *Int J Cancer* 2004;109:472–475.
80. Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. *Proc Natl Acad Sci U S A* 2006;103:15552–15557.
81. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. *Nat Genet* 2005;37:19–24.
82. Inoki K, Li Y, Xu T, et al. Rheb GTPase is a direct target of TSC2. GAP activity and regulates mTOR signaling. *Genes Dev* 2003;17:1829–1834.
83. Hasumi H, Baba M, Hong SB, et al. Identification and characterization of a novel folliculin-interacting protein FNIP2. *Gene* 2008;415:60–67.
84. Takagi Y, Kobayashi T, Shiono M, et al. Interaction of folliculin (Birt-Hogg-Dubé gene product) with a novel Fnip1-like (FnipL/Fnip2) protein. *Oncogene* 2008;27:5339–5347.
85. Baba M, Furihata M, Hong SB, et al. Kidney-targeted Birt-Hogg-Dubé gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. *J Natl Cancer Inst* 2008;100:140–154.
86. Hasumi Y, Baba M, Ajima R, et al. Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. *Proc Natl Acad Sci U S A* 2009;106:18722–18727.
87. van Slegtenhorst M, Khabibullin D, Hartman TR, et al. The Birt-Hogg-Dubé and tuberous sclerosis complex homologs have opposing roles in amino acid homeostasis in *Schizosaccharomyces pombe*. *J Biol Chem* 2007;282:24583–24590.
88. Hudon V, Sabourin S, Dydensborg AB, et al. Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin. *J Med Genet* 2010;47:182–189.
89. Hartman TR, Nicolas E, Klein-Szanto A, et al. The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. *Oncogene* 2009;28:1594–1604.
90. Cash TP, Gruber JJ, Hartman TR, et al. Loss of the Birt-Hogg-Dubé tumor suppressor results in apoptotic resistance due to aberrant TGFbeta-mediated transcription. *Oncogene* 2011;30:2534–2546.
91. Hong SB, Oh H, Valera VA, et al. Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling. *Molecular Cancer* 2010;9:160.
92. Preston RS, Philp A, Claessens T, et al. Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility. *Oncogene* 2011;30:1159–1173.
93. Luijten MN, Basten SG, Claessens T, et al. Birt-Hogg-Dubé syndrome is a novel ciliopathy. *Hum Mol Genet* 2013;22:4383–4397.
94. Klomp JA, Petillo D, Niemi NM, et al. Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression. *BMC Med Genomics* 2010;3:59.
95. Hasumi H, Baba M, Hasumi Y, et al. Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN. *J Natl Cancer Inst* 2012;104:1750–1764.
96. Nahorski MS, Seabra L, Straatman-Iwanowska A, et al. Folliculin interacts with p0071 (plakophilin-4) and deficiency is associated with disordered RhoA signalling, epithelial polarization and cytokinesis. *Hum Mol Genet* 2012;21:5268–5279.
97. Medvetz DA, Khabibullin D, Hariharan V, et al. Folliculin, the product of the Birt-Hogg-Dubé tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion. *PLoS One* 2012;7:e47842.
98. Betschinger J, Nichols J, Dietmann S, et al. Exit from pluripotency is gated by intracellular redistribution of the bHLH transcription factor Tfe3. *Cell* 2013;153:335–347.
99. Hong SB, Oh H, Valera VA, et al. Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. *PLoS ONE* 2010;5:e15793.
100. Petit CS, Roczniak-Ferguson A, Ferguson SM. Recruitment of folliculin to lysosomes supports the amino acid-dependent activation of Rag GTPases. *J Cell Biol* 2013;202:1107–1122.
101. Nookala RK, Langemeyer L, Pacitto A, et al. Crystal structure of folliculin reveals a hidDenn function in genetically inherited renal cancer. *Open Biol* 2012;2:120071.
102. Tsun ZY, Bar-Peled L, Chantranupong L, et al. The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1. *Mol Cell* 2013;52:495–505.
103. Baba M, Keller JR, Sun HW, et al. The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dubé syndrome is required for murine B-cell development. *Blood* 2012;120:1254–1261.
104. Kiuru M, Launonen V. Hereditary leiomyomatosis and renal cell cancer (HLRCC). *Curr Mol Med* 2004;4:869–875.
105. Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. *J Med Genet* 2006;43:18–27.
106. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. *Am J Hum Genet* 2003;73:95–106.
107. Alam NA, Bevan S, Churchman M, et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. *Am J Hum Genet* 2001;68:1264–1269.
108. Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. *Proc Natl Acad Sci U S A* 2001;98:3387–3392.
109. Alam NA, Rowan AJ, Wortham NC, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. *Hum Mol Genet* 2003;12:1241–1252.
110. Bayley JP, Launonen V, Tomlinson IP. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. *BMC Med Genet* 2008;9:20.
111. Kiuru M, Lehtonen R, Arola J, et al. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. *Cancer Res* 2002;62:4554–4557.
112. Pithukpakorn M, Wei MH, Toure O, et al. Fumarate hydratase enzyme activity in lymphoblastoid cells and fibroblasts of individuals in families with hereditary leiomyomatosis and renal cell cancer. *J Med Genet* 2006;43:755–762.
113. Pollard PJ, Briere JJ, Alam NA, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. *Hum Mol Genet* 2005;14:2231–2239.
114. Isaacs JS, Jung YJ, Mole DR, et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. *Cancer Cell* 2005;8:143–153.
115. Pollard P, Wortham N, Barclay E, et al. Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. *J Pathol* 2005;205:41–49.
116. Xiao M, Yang H, Xu W, et al. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. *Genes Dev* 2012;26:1326–1338.
117. Sudarshan S, Sourbier C, Kong HS, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and HIF-1 alpha stabilization by glucose-dependent generation of reactive oxygen species. *Mol Cell Biol* 2009;15:4080–4090.
118. Sullivan LB, Garcia-Martinez E, Nguyen H, et al. The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. *Mol Cell* 2013;51:236–248.
119. Kansanen E, Kuosmanen SM, Leinonen H, et al. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. *Redox Biol* 2013;1:45–49.
120. Ooi A, Wong JC, Petillo D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. *Cancer Cell* 2011;20:511–523.
121. Adam J, Hatipoglu E, O'Flaherty L, et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. *Cancer Cell* 2011;20:524–537.

122. Ooi A, Dykema K, Ansari A, et al. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. *Cancer Res* 2013;73:2044–2051.
123. Frezza C, Zheng L, Folger O, et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. *Nature* 2011;477:225–228.
124. Mullen AR, Wheaton WW, Jin ES, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. *Nature* 2011;481:385–388.
125. Yang Y, Lane AN, Fan TW, et al. Metabolic reprogramming for producing energy and reducing power in Fumarate Hydratase null cells from hereditary leiomyomatosis renal cell carcinoma. *PLoS One* 2013;8:e72179.
126. Srirangalingam U, Walker L, Khoo B, et al. Clinical manifestations of familial paraganglioma and pheochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. *Clin Endocrinol (Oxf)* 2008;69:587–596.
127. Henderson A, Douglas F, Perros P, et al. SDHB-associated renal oncocytoma suggests a broadening of the renal phenotype in hereditary paragangliomatosis. *Fam Cancer* 2009;8:257–260.
128. Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. *J Natl Cancer Inst* 2008;100:1260–1262.
129. Astuti D, Douglas F, Lennard TW, et al. Germline SDHD mutation in familial pheochromocytoma. *Lancet* 2001;357:1181–1182.
130. Pawlu C, Bausch B, Neumann HP. Mutations of the SDHB and SDHD genes. *Fam Cancer* 2005;4:49–54.
131. Astuti D, Latif F, Dallol A, et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. *Am J Hum Genet* 2001;69:49–54.
132. Ricketts CJ, Forman JR, Rattenberry E, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. *Hum Mutat* 2010;31:41–51.
133. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. *N Engl J Med* 2006;355:1345–1356.
134. van Slechtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. *Science* 1997;277:805–808.
135. The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. *Cell* 1993;75:1305–1315.
136. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. *Cancer Cell* 2004;6:91–99.
137. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. *N Engl J Med* 2008;358:140–151.